Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000899243-20-023230
Filing Date
2020-08-21
Accepted
2020-08-21 18:23:43
Documents
1
Period of Report
2020-08-20

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 4191
  Complete submission text file 0000899243-20-023230.txt   5615
Mailing Address 300 TECHNOLOGY SQUARE 2ND FLOOR CAMBRIDGE MA 02139
Business Address 300 TECHNOLOGY SQUARE 2ND FLOOR CAMBRIDGE MA 02139 857-285-5314
Kymera Therapeutics, Inc. (Issuer) CIK: 0001815442 (see all company filings)

EIN.: 812992166 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O BESSEMER VENTURE PARTNERS 1865 PALMER AVENUE SUITE 104 LARCHMONT NY 10538
Business Address
Hedin Andrew (Reporting) CIK: 0001821049 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39460 | Film No.: 201124363